Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-025029
Filing Date
2025-02-21
Accepted
2025-02-21 18:00:06
Documents
1
Period of Report
2025-02-19

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5435
  Complete submission text file 0000950170-25-025029.txt   7169
Mailing Address C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Business Address
AHMED NADIM (Reporting) CIK: 0001731193 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39856 | Film No.: 25653511

Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Issuer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)